Search research articles
Contact Us
Filters
Showing results (91-100 of 104) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic
Chad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Cancer
|
November 1, 2005
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer
Ralph G Zinner, Frank V Fossella, Gregory W Gladish, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 12, 2004
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease
Ralph G Zinner, Bonnie S Glisson, Frank V Fossella, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic
Denis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2014
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer
Ralph G Zinner, Coleman K Obasaju, David R Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 12, 2025
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial
Ralph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 31, 2004
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial
Ritsuko Komaki, Jin Soo Lee, Luka Milas, et al.
Oncotarget
|
May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget
|
September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 104) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic
Chad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Cancer
|
November 1, 2005
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer
Ralph G Zinner, Frank V Fossella, Gregory W Gladish, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 12, 2004
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease
Ralph G Zinner, Bonnie S Glisson, Frank V Fossella, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic
Denis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2014
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer
Ralph G Zinner, Coleman K Obasaju, David R Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 12, 2025
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial
Ralph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 31, 2004
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial
Ritsuko Komaki, Jin Soo Lee, Luka Milas, et al.
Oncotarget
|
May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget
|
September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Page
of 11